2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
McGuire TF et al. | Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. | 1996 | J. Biol. Chem. | pmid:8910319 |
Umetani N et al. | Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. | 1996 | Biochim. Biophys. Acta | pmid:8908154 |
Satoh T et al. | The effects of pravastatin, an HMG-CoA reductase inhibitor, on cell viability and DNA production of rat hepatocytes. | 1996 | Life Sci. | pmid:8831797 |
Miquel K et al. | Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. | 1996 | Biochem. Biophys. Res. Commun. | pmid:8780704 |
Nishio E et al. | 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell p4fferentiation in cultured adipogenic cells (3T3-L1). | 1996 | Eur. J. Pharmacol. | pmid:8773465 |
Koyama T et al. | Identification of significant residues in the substrate binding site of Bacillus stearothermophilus farnesyl diphosphate synthase. | 1996 | Biochemistry | pmid:8755734 |
Tanaka H et al. | MEKA/phosducin attenuates hydrophobicity of transducin beta gamma subunits without binding to farnesyl moiety. | 1996 | Biochem. Biophys. Res. Commun. | pmid:8687440 |
Crick DC et al. | Geranylgeraniol restores cell proliferation to lovastatin treated C6 glial cells. | 1996 | SAAS Bull. Biochem. Biotechnol. | pmid:8652130 |
Keller RK et al. | Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. | 1996 | Arch. Biochem. Biophys. | pmid:8645011 |
Roullet JB et al. | Farnesyl analogues inhibit vasoconstriction in animal and human arteries. | 1996 | J. Clin. Invest. | pmid:8636420 |